Guggenheim analyst Seamus Fernandez lowered the firm’s price target on GSK to 1,922 GBp from 2,092 GBp and keeps a Buy rating on the shares. The firm is updating its model following competitor data for long-acting HIV PrEP, the June ACIP RSV updates and for prescription and forex trends. The firm recognizes that the Zantac Delaware Daubert decision may keep the stock range-bound barring a Delaware Supreme Court decision to hear an expedited appeal, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK Pharma put volume heavy and directionally bearish
- iTeos Therapeutics announces first patient dosed in GALAXIES Lung-301 study
- GSK downgraded to Neutral from Buy at UBS
- FDA to evaluate potential risk of neural tube birth defects with dolutegravir
- GSK Acquires Key Vaccine Rights from Partner CureVac in €1.45B Deal